PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 201 filers reported holding PUMA BIOTECHNOLOGY INC in Q1 2015. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $50,000 | -23.1% | 7,106 | 0.0% | 0.00% | – |
| Q2 2021 | $65,000 | -5.8% | 7,106 | 0.0% | 0.00% | – |
| Q1 2021 | $69,000 | -5.5% | 7,106 | 0.0% | 0.00% | – |
| Q4 2020 | $73,000 | +1.4% | 7,106 | 0.0% | 0.00% | – |
| Q3 2020 | $72,000 | -2.7% | 7,106 | 0.0% | 0.00% | – |
| Q2 2020 | $74,000 | +23.3% | 7,106 | 0.0% | 0.00% | – |
| Q1 2020 | $60,000 | +13.2% | 7,106 | +16.8% | 0.00% | – |
| Q4 2019 | $53,000 | -19.7% | 6,086 | 0.0% | 0.00% | – |
| Q3 2019 | $66,000 | -14.3% | 6,086 | 0.0% | 0.00% | – |
| Q2 2019 | $77,000 | -67.4% | 6,086 | 0.0% | 0.00% | -100.0% |
| Q1 2019 | $236,000 | +90.3% | 6,086 | 0.0% | 0.00% | +100.0% |
| Q4 2018 | $124,000 | -55.6% | 6,086 | 0.0% | 0.00% | -50.0% |
| Q3 2018 | $279,000 | -22.5% | 6,086 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $360,000 | -13.0% | 6,086 | 0.0% | 0.00% | -33.3% |
| Q1 2018 | $414,000 | -35.3% | 6,086 | -5.9% | 0.00% | -25.0% |
| Q4 2017 | $640,000 | -17.4% | 6,471 | 0.0% | 0.00% | -33.3% |
| Q3 2017 | $775,000 | +36.9% | 6,471 | 0.0% | 0.01% | +50.0% |
| Q2 2017 | $566,000 | +134.9% | 6,471 | 0.0% | 0.00% | +100.0% |
| Q1 2017 | $241,000 | +21.1% | 6,471 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $199,000 | -54.1% | 6,471 | 0.0% | 0.00% | -50.0% |
| Q3 2016 | $434,000 | +124.9% | 6,471 | 0.0% | 0.00% | +100.0% |
| Q2 2016 | $193,000 | -9.8% | 6,471 | -11.0% | 0.00% | 0.0% |
| Q1 2016 | $214,000 | -62.5% | 7,274 | -0.0% | 0.00% | -60.0% |
| Q4 2015 | $570,000 | +4.0% | 7,275 | +0.1% | 0.01% | 0.0% |
| Q3 2015 | $548,000 | -35.5% | 7,268 | -0.1% | 0.01% | -28.6% |
| Q2 2015 | $850,000 | -44.4% | 7,277 | +12.5% | 0.01% | -46.2% |
| Q1 2015 | $1,528,000 | +24.7% | 6,471 | 0.0% | 0.01% | +30.0% |
| Q4 2014 | $1,225,000 | -20.7% | 6,471 | 0.0% | 0.01% | -23.1% |
| Q3 2014 | $1,544,000 | +119.6% | 6,471 | -39.2% | 0.01% | +116.7% |
| Q2 2014 | $703,000 | – | 10,651 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HARVARD MANAGEMENT CO INC | 600,000 | $45,216,000 | 3.56% |
| Avalon Global Asset Management LLC | 32,900 | $2,479,000 | 1.79% |
| CORNERSTONE CAPITAL MANAGEMENT LLC | 495,145 | $37,314,000 | 1.58% |
| BB BIOTECH AG | 521,991 | $39,337,000 | 1.25% |
| WEATHERBIE CAPITAL, LLC | 137,041 | $10,327,000 | 1.20% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $428,527,000 | 1.19% |
| TOBAM | 318,384 | $23,994,000 | 0.94% |
| Orbimed Advisors | 1,195,500 | $90,093,000 | 0.91% |
| Capital International Sarl | 109,405 | $8,245,000 | 0.74% |
| CAPITAL INTERNATIONAL LTD /CA/ | 145,697 | $10,980,000 | 0.73% |